摘要
目的 评估慢性乙型肝炎及其并发症的经济负担和拉米夫定治疗的临床效果与经济效益。方法 根据慢性乙型肝炎、代偿性肝硬化、失代偿性肝硬化和肝癌病人的年直接医疗费用、直接非医疗费用以及间接费用计算其经济负担。同时根据亚洲拉米夫定多中心临床研究和 15个国家临床研究的综合数据来计算节省的费用。结果 不同肝病阶段的病人年经济负担不同 ,慢性乙型肝炎为 2 0 478元 ,代偿性肝硬化为 3 63 2 5元 ,失代偿性肝硬化为 3 675 9元 ,肝细胞肝癌为 3 82 69元。拉米夫定治疗 1年后 ,使医疗费用得到部分节省。结论 慢性乙型肝炎病毒感染者经济负担较重 。
Objective To evaluate the economic burden of chronic hepatitis B(CHB) and it's complications, and to evaluate the benefits of treatment with lamivudine. Methods The components of the economic burden of disease included direct medical costs and non medical costs as well as indirect economic loss per patient year in patients with chronic hepatitis B virus infections, including chronic hepatitis B, compensated and decompensated cirrhosis, and hepatocellular carcinoma. Net cost savings due to treatment of CHB with lamivudine were estimated using clinical data from an Asian multicentre lamivudine clinical study and GSK lamuvidine clinical trials pooled analysis of 15 countries. Results Our results indicate that CHB and its complications created significant economic burden on the patients and their families. Further, more the net cost savings resulted following 1 year treatment of lamivudine due to reduction in the rate of progression to liver cirrhosis.Conclusion CHB infections create a heavy economic burden on the society, as well as patients and their families. We have seen the potential cost savings due to treatment with lamivudine.
出处
《肝脏》
2002年第2期79-81,共3页
Chinese Hepatology
